myAACR
Donate Today
Skip to Content

Progress Against Cancer

Home Patients, Caregivers, and Advocates Progress Against Cancer Research Page 2

Recent Progress

A New Immunotherapy for Esophageal Cancer 

A New Immunotherapy for Esophageal Cancer 

Tislelizumab-jsgr received its first FDA approval to treat certain esophageal cancers.  The U.S. Food and Drug Administration (FDA) has approved tislelizumab-jsgr (Tevimbra) for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who...